The Claim

In Pkd1RC/RC mice, five months of fenofibrate treatment significantly reduces total kidney volume, total cyst volume, kidney-weight-to-body-weight ratio, cyst index, and serum creatinine levels compared to untreated littermates, suggesting attenuation of polycystic kidney disease progression in this animal model.

Source: PPARα agonist fenofibrate enhances fatty acid β-oxidation and attenuates polycystic kidney and liver disease in mice.

What the research says

Supports is higher

Support is ahead, but a single strong opposing study can change this.

Supports
12score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

Correlation
1 study reviewed
In plain English

Fenofibrate seems to slow down kidney disease in mice with a condition similar to polycystic kidney disease, making their kidneys healthier after five months of treatment.

See the scientific wording

In Pkd1RC/RC mice, fenofibrate treatment for 5 months is associated with significantly reduced total kidney volume, total cyst volume, kidney-weight-to-body-weight ratio, cyst index, and serum creatinine levels compared to untreated littermates, indicating attenuation of polycystic kidney disease progression in this animal model.

What the research says

1 study

  1. Study: PPARα agonist fenofibrate enhances fatty acid β-oxidation and attenuates polycystic kidney and liver disease in mice.

    The study gave fenofibrate to mice with a disease like polycystic kidney disease for 5 months and found their kidney problems got better, just like the claim says.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.